Rocket Lab stock jumps after Morgan Stanley upgrade as RKLB tests fresh highs

Rocket Lab stock jumps after Morgan Stanley upgrade as RKLB tests fresh highs

New York, Jan 16, 2026, 10:39 EST — Regular session

  • Rocket Lab shares jump following Morgan Stanley’s upgrade and higher price target.
  • This comes after KeyBanc downgraded the stock, citing “priced-in” catalysts.
  • Traders are eyeing updates on Neutron’s timeline alongside the upcoming earnings date window.

Shares of Rocket Lab Corp (RKLB) jumped roughly 6% on Friday following an upgrade from Morgan Stanley, signaling renewed investor faith in the space launch and satellite firm. The stock climbed 6.4% to $96.61 in morning trading. 1

The upgrade is crucial now as investors remain divided over whether Rocket Lab’s rally can sustain itself without fresh catalysts. The coming weeks could shake the stock, hinging on updates about the Neutron rocket timeline and the speed of government contract awards.

On Thursday, KeyBanc Capital Markets cut Rocket Lab’s rating to “sector weight” from “overweight,” noting that recent milestones appear priced into the stock and that the near-term risk-reward is fairly even. The firm uses “overweight” to signal expected outperformance, while “sector weight” suggests a more neutral stance. 2

On Friday, Morgan Stanley flipped the script, calling space technology “Attractive” for 2026 and upgrading Rocket Lab to “overweight,” with a price target boost to $105 from $67. Analyst Kristine Liwag pointed to “higher launch cadences, new product intros, policy support & market maturation” driving the sector next year. At the time, the S&P 500 and Nasdaq dipped roughly 0.2%. 3

Rocket Lab is increasingly leaning on defense and national security contracts. In December, the company secured an $816 million deal with the Space Development Agency to build 18 satellites for its Tracking Layer Tranche 3 program — a U.S. Space Force initiative targeting missile warning and tracking. Rocket Lab expects additional subsystem sales could push the total opportunity close to $1 billion. Founder and CEO Peter Beck said the company was “honored to play a role in enabling this.” 4

Investors are watching insider moves closely in these hot momentum stocks. Director Merline Saintil sold 108,500 shares this week in two separate transactions. That included a 96,000-share transfer into an exchange fund and a 12,500-share sale under a Rule 10b5-1 trading plan, according to a Form 4 filing. 5

The key issue remains execution. If Neutron’s launch stumbles or Rocket Lab falls short of its projected launch pace, the stock’s premium valuation compared to established aerospace rivals could come under pressure.

Rocket Lab is set to release its next earnings report near Feb. 26, per Public.com’s earnings calendar. Traders will be watching closely for a firm date and any fresh details that narrow the timeline for Neutron’s inaugural launch. 6

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line
Previous Story

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

American Airlines stock slides as United rivalry at O’Hare sharpens — what to watch next
Next Story

American Airlines stock slides as United rivalry at O’Hare sharpens — what to watch next

Go toTop